BAT1706 + carboplatin + paclitaxel

The combination of BAT1706 (a proposed bevacizumab biosimilar), carboplatin, and paclitaxel is a therapeutic regimen primarily studied for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). This combination was evaluated in a Phase III clinical trial (NCT03329911) that compared BAT1706 plus paclitaxel and carboplatin to EU-bevacizumab plus paclitaxel and carboplatin[1][7]. ## Clinical Trial Design and Administration The Phase III trial was a randomized, double-blind, multi-center study that enrolled 649 patients who received at least one cycle of combination treatment[1]. Patients were randomized 1:1 to receive either BAT1706 plus paclitaxel and carboplatin or EU-bevacizumab plus paclitaxel and carboplatin[2]. The administration schedule was carefully designed: - For cycle 1, day 1: Only BAT1706 or EU-bevacizumab was given - On day 2: Paclitaxel and carboplatin were administered - From cycle 2 (day 22) to cycle 6: BAT1706 or EU-bevacizumab was administered first, followed by paclitaxel and then carboplatin on the same day[7] This sequence is important as research has shown that paclitaxel must be given before carboplatin because if carboplatin is given before paclitaxel, it inhibits paclitaxel's effect on cancer cells[6]. ## Efficacy Results The primary endpoint of the study was overall response rate at Week 18 (ORR18). The results showed: - ORR18 was comparable between the BAT1706 and EU-bevacizumab arms (48.0% and 44.5%, respectively) - The ORR18 risk ratio was 1.08 (90% CI: 0.94-1.24) - The ORR18 risk difference was 0.03 (95% CI: -0.04 to 0.11)[1][7] These results were within the predefined equivalence margins, demonstrating the biosimilarity of BAT1706 to EU-bevacizumab when used in this combination therapy[1]. ## Safety Profile The safety profile of BAT1706 in combination with paclitaxel and carboplatin was consistent with that of EU-bevacizumab plus paclitaxel and carboplatin, with no new safety signals observed[1]. This is significant as it supports the use of BAT1706 as a biosimilar alternative to bevacizumab in this treatment regimen. After six cycles of combination therapy, patients with complete response, partial response, or stable disease received maintenance therapy with either BAT1706 or EU-bevacizumab for up to 12 months after week 18[7]. This combination represents an important treatment option for patients with advanced non-squamous NSCLC, offering a potentially more accessible biosimilar alternative while maintaining equivalent efficacy and safety to the reference product.